Zoetis (ZTS) Non-Current Assets (2012 - 2026)
Zoetis (ZTS) posted quarterly Non-Current Assets of $8.7 billion for Q1 2026, up 5.58% year-over-year from $8.2 billion in Q1 2025, and little changed quarter-over-quarter from $8.7 billion in Q4 2025.
Zoetis (ZTS) Non-Current Assets (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Non-Current Assets for 15 consecutive years, with $8.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 5.58% year-over-year to $8.7 billion; the TTM figure through Mar 2026 stood at $34.5 billion (up 6.33% YoY), while the FY2025 annual figure was $8.7 billion, up 6.12% from the prior year.
- Non-Current Assets held at $8.7 billion in Q1 2026 per ZTS's latest filing, from $8.7 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $8.7 billion in Q4 2025 and bottomed at $7.0 billion in Q1 2022.
- Historically, Non-Current Assets has averaged $7.9 billion across 5 years, with a median of $8.0 billion in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets advanced 0.3% — and 2023, when it climbed 10.68%.
- Zoetis' Non-Current Assets stood at $7.4 billion in 2022, then climbed by 7.06% to $7.9 billion in 2023, then increased by 3.41% to $8.2 billion in 2024, then increased by 6.12% to $8.7 billion in 2025, then declined by 0.42% to $8.7 billion in 2026.
- Business Quant data shows ZTS's Non-Current Assets at $8.7 billion in Q1 2026, $8.7 billion in Q4 2025, and $8.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 2.96 Bn |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn | 2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.72 Bn |
| Mar 31, 2026 | 8.68 Bn |
| Dec 31, 2025 | 8.72 Bn |
| Sep 30, 2025 | 8.58 Bn |
| Jun 30, 2025 | 8.56 Bn |
| Mar 31, 2025 | 8.22 Bn |
| Dec 31, 2024 | 8.21 Bn |
| Sep 30, 2024 | 8.08 Bn |
| Jun 30, 2024 | 7.96 Bn |
| Mar 31, 2024 | 7.99 Bn |
| Dec 31, 2023 | 7.94 Bn |
| Sep 30, 2023 | 7.88 Bn |
| Jun 30, 2023 | 7.57 Bn |
| Mar 31, 2023 | 7.49 Bn |
| Dec 31, 2022 | 7.42 Bn |
| Sep 30, 2022 | 7.12 Bn |
| Jun 30, 2022 | 7.12 Bn |
| Mar 31, 2022 | 7.02 Bn |
| Dec 31, 2021 | 6.97 Bn |
| Sep 30, 2021 | 7.02 Bn |